2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Polycystic Ovary Syndrome
10
Insulin Resistance
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Prostatic Neoplasms
4
Diabetes Mellitus, Type 2
4
Pancreatic Neoplasms
3
Diabetes Mellitus
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Metabolic Syndrome
2
Leukoplakia, Oral
2
Leukemia, Myeloid, Chronic-Phase
2
Inflammation
2
Carotid Intimal Medial Thickness 1
2
Breast Neoplasms
2
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Pharmacokinetics of MDV3100
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Meningioma
1
Memory Disorders
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
561
Azacitidine
385
venetoclax
311
Cyclophosphamide
289
fludarabine
246
fludarabine phosphate
229
Decitabine
187
Busulfan
176
Daunorubicin
155
Idarubicin
151
Peripheral Blood Stem Cell Transplantation
138
Mycophenolic Acid
134
Filgrastim
134
Whole-Body Irradiation
133
Tacrolimus
125
Granulocyte Colony-Stimulating Factor
124
Etoposide
117
Mitoxantrone
103
Methotrexate
103
Melphalan
103
Cyclosporine
101
Antilymphocyte Serum
85
Gemtuzumab
84
Clofarabine
84
Specimen Handling
73
Injections
69
Stem Cell Transplantation
64
Biopsy
57
CPX-351
56
Thiotepa
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
Pioglitazone
×
Clear all
NCT02942758
2024-05-08
AML-ViVA
University Hospital Regensburg
Phase 2
Terminated
10 enrolled